In type 2 diabetes mellitus, long-acting GLP-1 RAs (dulaglutide, liraglutide, and subcutaneous semaglutide) have demonstrated a reduction in the risk of major adverse cardiovascular events compared to placebo in large cardiovascular outcome trials [102,103,104]. This evidence concerns the gene GCG and type 2 diabetes mellitus.